'Ldl 130 mg dl' diaporamas de présentation

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death. Placebo 251/8901. HR 0.56, 95% CI 0.46-0.69 P <0.00001. 0.08. 0.06. - 44 %. Cumulative Incidence. 0.04. Rosuvastatin 142 / 8901. 0.02. 0.00. 0. 1. 2. 3. 4. Follow-up (years). Number at Risk.

824 views • 54 slides

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death. Placebo 251/8901. HR 0.56, 95% CI 0.46-0.69 P <0.00001. 0.08. 0.06. - 44 %. Cumulative Incidence. 0.04. Rosuvastatin 142 / 8901. 0.02. 0.00. 0. 1. 2. 3. 4. Follow-up (years). Number at Risk.

546 views • 54 slides

Hyperlipidemia/Dyslipidemia

Hyperlipidemia/Dyslipidemia. J.B. Handler, M.D. Physician Assistant Program University of New England. LDL- low density lipoprotein HDL- high density lipoprotein IDL- intermediate density lipprotein VLDL- very low density lipoprotein Lp(a)- lipoprotein a CAD- coronary artery disease

1.69k views • 48 slides

Journal Club

844 views • 41 slides

JAMA 1998;279:1615-1622

Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels Results of AFCAPS/TexCAPS.

324 views • 32 slides

Presenter Disclosure Information

Presenter Disclosure Information. Paul M Ridker, MD, FACC.

401 views • 27 slides

Presenter Disclosure Information

JUPITER ACC March 30, 2009. Presenter Disclosure Information. Disclosure Information: Paul M Ridker, MD, FACC.

417 views • 27 slides

Presenter Disclosure Information

JUPITER ACC March 30, 2009. Presenter Disclosure Information. Disclosure Information: Paul M Ridker, MD, FACC.

381 views • 27 slides

JUPITER ACC March 30, 2009

JUPITER ACC March 30, 2009. CRP Reduction, LDL Reduction, and Cardiovascular Event Rates After Initiation of Rosuvastatin: The JUPITER Trial Paul Ridker*, Eleanor Danielson, Francisco Fonseca*, Jacques Genest*, Antonio Gotto*, John Kastelein*, Wolfgang Koenig*, Peter Libby*,

405 views • 26 slides